This company listing is no longer active
Zynex (ZYXI.Q) Stock Overview
Designs, manufactures, and markets medical devices to treat chronic and acute pain, and activate and exercise muscles for rehabilitative purposes with electrical stimulation. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ZYXI.Q Community Fair Values
Create NarrativeSee what 20 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Zynex, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.055 |
| 52 Week High | US$2.82 |
| 52 Week Low | US$0.02 |
| Beta | 1.08 |
| 1 Month Change | -38.89% |
| 3 Month Change | -19.12% |
| 1 Year Change | -97.56% |
| 3 Year Change | -99.54% |
| 5 Year Change | -99.61% |
| Change since IPO | -97.43% |
Recent News & Updates
ZYXI.Q: Forward P/E Will Highlight Bullish Upside Through Chapter 11 Process
Analysts have slightly raised their price target on Zynex to reflect updated assumptions around profit margins and a modestly higher future P/E, while keeping fair value and discount rate unchanged. What's in the News Zynex, Inc.ZYXI.Q: Forward Earnings Multiple Will Signal Bullish Opportunity Despite Chapter 11 Proceedings
Analysts have revised their price target on Zynex, confirming it at US$3.70. This reflects unchanged fair value and operating assumptions in their updated models.Recent updates
ZYXI.Q: Forward P/E Will Highlight Bullish Upside Through Chapter 11 Process
Analysts have slightly raised their price target on Zynex to reflect updated assumptions around profit margins and a modestly higher future P/E, while keeping fair value and discount rate unchanged. What's in the News Zynex, Inc.ZYXI.Q: Forward Earnings Multiple Will Signal Bullish Opportunity Despite Chapter 11 Proceedings
Analysts have revised their price target on Zynex, confirming it at US$3.70. This reflects unchanged fair value and operating assumptions in their updated models.ZYXI: Forward Earnings Multiple Will Drive Bullish Opportunity Despite Filing Delay
Analysts have modestly lifted their price target on Zynex, raising it by $0.18 per share as they balance a slightly higher required return with resilient growth assumptions and a still attractive forward earnings multiple. What's in the News Announced it will be unable to file its next Form 10 Q with the SEC by the required deadline, signaling a delayed quarterly report that may raise short term compliance and transparency concerns (SEC filing) Valuation Changes Discount Rate has risen slightly from 12.0 percent to 12.5 percent, reflecting a modestly higher required return on equity.ZYXI: Future Earnings Multiple Drop and 10-Q Delay Will Drive New Opportunities
Analysts have raised their price target for Zynex from $3.70 to $7.57 per share, citing higher projected revenue growth and a slightly lower discount rate as key factors supporting the positive revision. What's in the News On November 12, 2025, Zynex, Inc.ZYXI: Net Profit Margin Is Expected To Improve Despite Filing Delay
Analysts have raised their fair value price target for Zynex from $2.85 to $3.70 per share. They cite revised assumptions about higher profitability and updated discount rates, even though they expect slightly weaker revenue growth.Investors Don't See Light At End Of Zynex, Inc.'s (NASDAQ:ZYXI) Tunnel And Push Stock Down 28%
The Zynex, Inc. ( NASDAQ:ZYXI ) share price has fared very poorly over the last month, falling by a substantial 28...Is Zynex (NASDAQ:ZYXI) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Zynex, Inc.'s (NASDAQ:ZYXI) Shares Bounce 41% But Its Business Still Trails The Industry
Zynex, Inc. ( NASDAQ:ZYXI ) shareholders are no doubt pleased to see that the share price has bounced 41% in the last...Here's Why It's Unlikely That Zynex, Inc.'s (NASDAQ:ZYXI) CEO Will See A Pay Rise This Year
Key Insights Zynex will host its Annual General Meeting on 15th of May CEO Thomas Sandgaard's total compensation...Capital Allocation Trends At Zynex (NASDAQ:ZYXI) Aren't Ideal
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...More Unpleasant Surprises Could Be In Store For Zynex, Inc.'s (NASDAQ:ZYXI) Shares After Tumbling 66%
The Zynex, Inc. ( NASDAQ:ZYXI ) share price has fared very poorly over the last month, falling by a substantial 66...Zynex's (NASDAQ:ZYXI) Returns On Capital Not Reflecting Well On The Business
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...Zynex (NASDAQ:ZYXI) Seems To Use Debt Quite Sensibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Zynex, Inc.: 2025 Looks Like A Brighter Year
Summary Zynex, Inc. focuses on non-opioid pain management and patient monitoring, with a recent FDA approval and a promising product pipeline. Analyst firms remain positive on the company's prospects, and Zynex has a strong balance sheet with no long-term debt and significant insider ownership. Profits will drop significantly in FY2024. However, earnings are projected to rebound sharply in FY2025 as sales growth accelerates. An updated analysis around Zynex, Inc. follows in the paragraphs below. Read the full article on Seeking Alpha
Calculated Diversification And Sales Optimization Set To Propel Long-Term Growth And Profitability
Enhancing future growth and stability through diversification of product lines and refining sales force efficiency, emphasizing long-term revenue and profitability.With Zynex, Inc. (NASDAQ:ZYXI) It Looks Like You'll Get What You Pay For
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 18x, you may...Earnings Update: Here's Why Analysts Just Lifted Their Zynex, Inc. (NASDAQ:ZYXI) Price Target To US$19.88
Investors in Zynex, Inc. ( NASDAQ:ZYXI ) had a good week, as its shares rose 5.5% to close at US$11.54 following the...Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts
The analysts might have been a bit too bullish on Zynex, Inc. ( NASDAQ:ZYXI ), given that the company fell short of...Why Investors Shouldn't Be Surprised By Zynex, Inc.'s (NASDAQ:ZYXI) P/E
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may...Shareholder Returns
| ZYXI.Q | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -21.4% | -2.5% | 2.0% |
| 1Y | -97.6% | -21.4% | 23.3% |
Return vs Industry: ZYXI.Q underperformed the US Medical Equipment industry which returned -11.8% over the past year.
Return vs Market: ZYXI.Q underperformed the US Market which returned 15.2% over the past year.
Price Volatility
| ZYXI.Q volatility | |
|---|---|
| ZYXI.Q Average Weekly Movement | 47.8% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ZYXI.Q's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ZYXI.Q's weekly volatility has increased from 35% to 48% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 1,000 | Steven Dyson | www.zynex.com |
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain, and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; and M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body; and batteries for use in electrotherapy products.
Zynex, Inc. Fundamentals Summary
| ZYXI.Q fundamental statistics | |
|---|---|
| Market cap | US$1.69m |
| Earnings (TTM) | -US$73.96m |
| Revenue (TTM) | US$108.20m |
Is ZYXI.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZYXI.Q income statement (TTM) | |
|---|---|
| Revenue | US$108.20m |
| Cost of Revenue | US$30.29m |
| Gross Profit | US$77.91m |
| Other Expenses | US$151.87m |
| Earnings | -US$73.96m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.40 |
| Gross Margin | 72.01% |
| Net Profit Margin | -68.35% |
| Debt/Equity Ratio | -143.4% |
How did ZYXI.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/28 03:53 |
| End of Day Share Price | 2026/03/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zynex, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Marc Wiesenberger | B. Riley Securities, Inc. |
| James Terwilliger | Northland Capital Markets |
| Adam Maeder | Piper Sandler Companies |